TY - JOUR T1 - Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2021-001697 VL - 8 IS - 1 SP - e001697 AU - Laurie Cachen AU - Gaetane Nocturne AU - Michael Collins AU - Antoine Meyer AU - Aude Gleizes AU - Salima Hacein-Bey-Abina AU - Franck Carbonnel AU - Xavier Mariette AU - Raphaele Seror Y1 - 2022/01/01 UR - http://rmdopen.bmj.com/content/8/1/e001697.abstract N2 - Objective To describe and identify factors associated with articular manifestations occurring in patients treated with anti-tumour necrosis factor (TNF) for inflammatory bowel diseases (IBDs).Methods Retrospective monocentric study, including all patients who received an anti-TNF for an IBD in our hospital. All incident articular manifestations occurring during treatment were analysed. Characteristics of patients with paradoxical articular manifestations were compared with that of patients without inflammatory articular manifestations.Results Between February 2013 and May 2017, we identified 442 patients (36.2±15 years, 50.5% men) who had ever received an anti-TNF for an IBD: Crohn’s disease (n=277), ulcerative colitis (n=154) and undetermined colitis (n=11). 115 (26%) patients developed new articular manifestations after a mean of 20 (±22) months of treatment. Among them, 59 (13.3%) had inflammatory manifestations: paradoxical in 39%, concomitant of an IBD flare in 27%, linked to an immunisation against anti-TNF in 27% and 7% to another diagnosis. Among paradoxical articular manifestations, 19 (83%) were new articular symptoms, including 8 (35%) de novo spondyloarthritis. There were no predictive factors of paradoxical articular manifestation. Paradoxical manifestations spontaneously resolved in 16 (70%) patients despite continuation of anti-TNF.Conclusion Inflammatory articular manifestations occurred in about 13% of patients treated with anti-TNF for IBD. More than a quarter were linked to an immunisation against anti-TNF, which has to be searched in this situation. About 40% were paradoxical. In most of cases, they were transitory and did not require anti-TNFs discontinuation.All data relevant to the study are included in the article or uploaded as online supplemental information. Raw data coming from electronic medical records cannot be shared. ER -